According to filings with the U.S. Securities and Exchange Commission, Elion Therapeutics is raising up to $83,835,000.00 in new funding. Sources indicate that as part of senior management Director, Jim Flynn played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Elion Therapeutics
A biotechnology company developing novel treatments that address critical unmet needs in antifungal efficacy and safety. Elion Therapeutics was founded on the understanding that mechanistic insights enable the targeted optimization of natural products. We hold this conviction at the core of our clinical development of the next-generation polyene SF001. Polyene antifungals were introduced in the 1950s. The first one, amphotericin B, quickly became widely known for its efficacy but also for its systemic toxicities, including severe renal toxicity. Later, lipid formulations were developed to mitigate against these toxicities, but they were only moderately safer. Since then, other classes of anitfungals have been introduced in the ongoing fight against invasive fungal infections. Nevertheless, challenges and unmet needs remain, underscoring the importance of continued drug development in the antifungal treatment landscape.

To learn more about Elion Therapeutics, visit http://eliontx.com/
Company Linkedin Page: https://www.linkedin.com/company/eliontx/

Contact:
Jim Flynn, Director
212-551-1600

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.